Studies of SARS virus vaccines.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hong Kong medical journal = Xianggang yi xue za zhi

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 18708674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection

  2008cited by this paper
• Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1

  2008cited by this paper
• Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

  2006cited by this paper
• Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines

  2006cited by this paper
• Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies

  2005cited by this paper
• Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice

  2004cited by this paper
• Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection

  2003cited by this paper

• Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19

  2020cites this paper
• Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2

  2020cites this paper
• A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection

  2016cites this paper
• Human Metapneumovirus Infections

  2014cites this paper